Canada markets close in 52 minutes

Ginkgo Bioworks Holdings, Inc. (DNA)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
1.8250-0.1750 (-8.75%)
As of 03:07PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close2.0000
Open1.9800
Bid1.8000 x 47300
Ask1.8100 x 45100
Day's Range1.8000 - 2.0000
52 Week Range1.4500 - 6.3000
Volume14,099,844
Avg. Volume23,287,919
Market Cap3.748B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ginkgo Bioworks and XpresCheck Expand CDC’s Traveler-Based Genomic Surveillance Program to Detect Influenza Variants

    The program is an effective early warning system for viral variants, leveraging voluntary sampling from international travelers at major U.S. airportsBOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA) and XWELL, Inc. (Nasdaq: XWEL) today announced that they have expanded their support for the Centers for Disease Control and Prevention’s (CDC’s) Traveler-based Genomic Surveillance program to include a pilot study monitoring influenza viruses in addition to SARS-CoV

  • GlobeNewswire

    Ginkgo Bioworks and XpresCheck Receive Award to Expand CDC’s Traveler-Based SARS-CoV-2 Genomic Surveillance Program In U.S. Airports

    Public-private partnership to enable the development of innovative, sustainable infrastructure designed to set the global standard for travel biosecurityBOSTON and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA) and XpresSpa Group, Inc. (Nasdaq: XSPA) announced they will continue to support the Centers for Disease Control and Prevention’s (CDC’s) traveler-based SARS-CoV-2 genomic surveillance program through a new contract awarded August 12, 2022. The partnership is expec

  • GlobeNewswire

    Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone

    TORONTO and BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos"), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”), the leading horizontal platform for cell programming, today announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo’s platform for organism design and development, Cronos has successfully achieved the productivity ta